Type 1 narcolepsy: A CD8+ T cell-mediated disease?

Annals of the New York Academy of Sciences

Volumn 1351, Issue 1, 2015, Pages 80-88

  Degn, Matilda ^a   Kornum, Birgitte Rahbek ^a  

^a University of Copenhagen   (Denmark)

Author keywords

Autoimmunity; Brain; CD8 T cell; Narcolepsy

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; OREXIN; HLA ANTIGEN CLASS 1;

ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; CD8+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NARCOLEPSY; NONHUMAN; PATHOGENESIS; TYPE 1 NARCOLEPSY; AUTOIMMUNITY; BRAIN; DEFICIENCY; IMMUNOLOGY; METABOLISM; NEUROLOGIC DISEASE; PHYSIOLOGY;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; BRAIN; CD8-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INFLAMMATION; NARCOLEPSY; NERVOUS SYSTEM DISEASES; OREXINS;

EID: 84941804726     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12793     Document Type: Article

References (67)

1. American Academy of Sleep Medicine. 2014. International Classification of Sleep Disorders-Third Edition (ICSD-3). Darien: American Academy of Sleep Medicine.
2. Partinen, M. et al. 2014. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol. 13: 600-613.
3. Nishino, S., B. Ripley, S. Overeem, et al. 2000. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355: 39-40.
4. Peyron, C. et al. 2000. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6: 991-997.
5. Thannickal, T.C. et al. 2000. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27: 469-474.
6. Bonnavion, P. & L. de Lecea 2010. Hypocretins in the control of sleep and wakefulness. Curr. Neurol. Neurosci. Rep. 10: 174-179.
7. Blouin, A.M. et al. 2005. Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy. Neurology 65: 1189-1192.
8. Crocker, A. et al. 2005. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 65: 1184-1188.
9. Partinen, M. et al. 2012. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One 7: e33723.
10. Han, F. et al. 2011. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in china. Ann. Neurol. 70: 410-417.
11. Longstreth, W.T., T.D. Koepsell, T.G. Ton, et al. 2007. The epidemiology of narcolepsy. Sleep 30: 13-26.
12. Aran, A. et al. 2009. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 32: 979-983.
13. Spelman, T. et al. 2014. Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. Ann. Neurol. 76: 880-890.
14. Juji, T., M. Satake, Y. Honda & Y. Doi 1984. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 24: 316-319.
15. Mignot, E. et al. 2001. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am. J. Hum.Genet. 68: 686-699.
16. Ollila, H.M. et al. 2015. HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy. Am. J. Hum. Genet. 96: 136-146.
17. Hallmayer, J. et al. 2009. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat. Genet. 41: 708-711.
18. Thannickal, T.C., J.M. Siegel, R. Nienhuis & R.Y. Moore 2003. Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol. 13: 340-351.
19. Cvetkovic-Lopes, V. et al. 2010. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J. Clin. Invest. 120: 713-719.
20. Dauvilliers, Y. et al. 2010. Post-H1N1 narcolepsy-cataplexy. Sleep 33: 1428-1430.
21. Wei, S.C. et al. 2012. Tribbles 2 (Trib2) is a novel regulator of Toll-like receptor 5 signaling. Inflamm. Bowel Dis. 18: 877-888.
22. Eder, K. et al. 2008. Tribbles-2 is a novel regulator of inflammatory activation of monocytes. Int. Immunol. 20: 1543-1550.
23. Bergman, P. et al. 2014. Narcolepsy patients have antibodies that stain distinct cell populations in rat brain and influence sleep patterns. Proc. Natl. Acad. Sci. U.S.A. 111: E3735-E3744.
24. Wiendl, H. et al. 2001. GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis. Neurology 57: 1511-1514.
25. Watson, R. et al. 2005. Alpha7-acetylcholine receptor antibodies in two patients with Rasmussen encephalitis. Neurology 65: 1802-1804.
26. Alvarez-Barón, E. et al. 2008. Autoantibodies to Munc18, cerebral plasma cells and B-lymphocytes in Rasmussen encephalitis. Epilepsy Res. 80: 93-97.
27. Varadkar, S. et al. 2014. Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances. Lancet. Neurol. 13: 195-205.
28. Jarius, S., B. Wildemann & F. Paul 2014. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin. Exp. Immunol. 176: 149-164.
29. Knudsen, S. et al. 2012. Early IVIg treatment has no effect on post-H1N1 narcolepsy phenotype or hypocretin deficiency. Neurology 79: 102-103.
30. Brown, D.M. 2010. Cytolytic CD4 cells: direct mediators in infectious disease and malignancy. Cell. Immunol. 262: 89-95.
31. Melzer, N., S.G. Meuth & H. Wiendl 2012. Neuron-directed autoimmunity in the central nervous system: entities, mechanisms, diagnostic clues, and therapeutic options. Curr. Opin. Neurol. 25: 341-348.
32. Bien, C.G. et al. 2002. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. Ann. Neurol. 51: 311-318.
33. + T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. Brain 132: 1236-1246.
34. Aye, M.M. et al. 2009. CD8 positive T-cell infiltration in the dentate nucleus of paraneoplastic cerebellar degeneration. J. Neuroimmunol. 208: 136-140.
35. Albert, M.L. et al. 1998. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. 4: 1321-1324.
36. Albert, M.L., L.M. Austin & R.B. Darnell 2000. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann. Neurol. 47: 9-17.
37. + T cells. J. Clin. Invest. 119: 2042-2051.
38. high T cell subset regulates TNF-mediated chronic murine ileitis. J. Immunol. 180: 2573-2580.
39. Dauvilliers, Y. et al. 2014. Cerebrospinal fluid and serum cytokine profiles in narcolepsy with cataplexy: a case-control study. Brain. Behav. Immun. 37: 260-266.
40. Kornum, B.R. et al. 2015. Cerebrospinal fluid cytokine levels in type 1 narcolepsy patients very close to onset. Brain. Behav. Immun. pii: S0889-1591(15)00075-6.
41. Vogt, J. et al. 2009. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann. Neurol. 66: 310-322.
42. Sospedra, M. & R. Martin 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23: 683-747.
43. Babbe, H. et al. 2000. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192: 393-404.
44. Neumann, H., I.M. Medana, J. Bauer & H. Lassmann 2002. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci. 25: 313-319.
45. + T cells in murine experimental allergic encephalomyelitis. Science 256: 1213-1215.
46. Ransohoff, R.M. & B. Engelhardt 2012. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat. Rev. Immunol. 12: 623-635.
47. Arima, Y. et al. 2012. Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier. Cell 148: 447-457.
48. Zhang, B., Y.K. Chan, B. Lu, et al. 2008. CXCR3 mediates region-specific antiviral T cell trafficking within the central nervous system during West Nile virus encephalitis. J. Immunol. 180: 2641-2649.
49. Gebhardt, T. & L.K. Mackay 2012. Local immunity by tissue-resident CD8(+) memory T cells. Front. Immunol. 3: 340.
50. + T cell differentiation. Nat. Rev. Immunol. 12: 749-761.
51. Sasaki, K. et al. 2014. Relapsing-remitting central nervous system autoimmunity mediated by GFAP-specific CD8 T cells. J. Immunol. 192: 3029-3042.
52. + T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc. Natl. Acad. Sci. U.S.A. 101: 2428-2433.
53. + T cells through a MHC class I- and granzyme B-dependent mechanism. Neurobiol. Dis. 59: 194-205.
54. Neumann, H., A. Cavalié, D.E. Jenne & H. Wekerle 1995. Induction of MHC class I genes in neurons. Science 269: 549-552.
55. Chevalier, G. et al. 2011. Neurons are MHC class I-dependent targets for CD8 T cells upon neurotropic viral infection. PLoS Pathog. 7: e1002393.
56. Cebrián, C. et al. 2014. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat. Commun. 5: 3633.
57. Huseby, E.S. et al. 2001. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J. Exp. Med. 194: 669-676.
58. Foster, J.A., N. Quan, E.L. Stern, et al. 2002. Induced neuronal expression of class I major histocompatibility complex mRNA in acute and chronic inflammation models. J. Neuroimmunol. 131: 83-91.
59. Scheikl, T. et al. 2012. Cutting Edge: neuronal recognition by CD8 T cells elicits central diabetes insipidus. J. Immunol. 188: 4731-4735.
60. Blachère, N.E. et al. 2014. T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation. Eur. J. Immunol. 44: 3240-3251.
61. Mor, F. & I.R. Cohen 2006. How special is a pathogenic CNS autoantigen? Immunization to many CNS self-antigens does not induce autoimmune disease. J. Neuroimmunol. 174: 3-11.
62. Huizinga, R., W. Gerritsen, N. Heijmans & S. Amor 2008. Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments. Neurobiol. Dis. 32: 461-470.
63. Puentes, F. et al. 2013. Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis. J. Neuroinflammation 10: 118.
64. Huh, G.S. et al. 2000. Functional requirement for class I MHC in CNS development and plasticity. Science 290: 2155-2159.
65. Fourgeaud, L. et al. 2010. MHC class I modulates NMDA receptor function and AMPA receptor trafficking. Proc. Natl. Acad. Sci. U.S.A. 107: 22278.
66. Gaykema, R.P.A. & L.E. Goehler 2009. Lipopolysaccharide challenge-induced suppression of Fos in hypothalamic orexin neurons: their potential role in sickness behavior. Brain. Behav. Immun. 23: 926-930.
67. Grossberg, A.J. et al. 2011. Inflammation-induced lethargy is mediated by suppression of orexin neuron activity. J. Neurosci. 31: 11376-1186.